미세잔존질환 검사 시장 보고서(2026년)

Minimal residual disease (MRD) testing is a highly sensitive diagnostic tool used to detect cancer cells that may remain in the patient's body after treatment. This test helps monitor the effectiveness of cancer treatments and guides future treatment strategies.

The main types of MRD testing include DNA-based tests, RNA-based tests, and immunological tests. DNA-based testing (also known as genetic testing) is a medical examination that identifies changes in chromosomes, genes, or proteins. Technologies used for MRD testing include flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others. These tests are applied in various contexts such as hematological malignancies, leukemia, lymphoma, and solid tumors. MRD testing is utilized by hospitals, specialty clinics, diagnostic laboratories, academic and research institutions, and other healthcare providers.

Tariffs have influenced the minimal residual disease testing market by increasing the cost of importing advanced diagnostic equipment and reagents, especially from major manufacturing hubs in Europe and North America. This has impacted the DNA- and RNA-based test segments the most, slowing adoption in regions like Asia-Pacific and Latin America. However, tariffs are also encouraging local manufacturing and investment in domestic diagnostic capabilities, which may enhance supply chain resilience and reduce long-term dependency on imports.

The minimal residual disease testing market research report is one of a series of new reports from The Business Research Company that provides minimal residual disease testing market statistics, including minimal residual disease testing industry global market size, regional shares, competitors with a minimal residual disease testing market share, detailed minimal residual disease testing market segments, market trends and opportunities, and any further data you may need to thrive in the minimal residual disease testing industry. This minimal residual disease testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The minimal residual disease testing market size has grown rapidly in recent years. It will grow from $1.8 billion in 2025 to $2.02 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to growing prevalence of hematological malignancies, advancements in molecular diagnostic technologies, rising awareness about minimal residual disease, increasing adoption of precision medicine, supportive government healthcare initiatives.

The minimal residual disease testing market size is expected to see rapid growth in the next few years. It will grow to $3.31 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to technological advancements in nGS and digital PCR, expansion of cancer research funding, increasing collaborations between diagnostic and pharmaceutical companies, rising demand for personalized treatment monitoring, growth in emerging markets healthcare infrastructure. Major trends in the forecast period include liquid biopsy adoption, personalized cancer monitoring, early detection & prognosis improvement, integration of molecular diagnostics, expansion of oncology research.

The rising prevalence of cancer is expected to drive the growth of the minimal residual disease (MRD) testing market. Cancer is a condition in which some of the body's cells grow uncontrollably and spread to other parts of the body. MRD testing is a highly sensitive method used to detect cancer cells in the body, and it plays a critical role in determining cancer stages. This early detection helps in preventing the disease at an early stage, thus contributing to the growth of the MRD testing market. For example, in January 2023, the National Institutes of Health (NIH), a U.S.-based government agency, projected that in 2023, there would be 1,958,310 new cancer cases and 609,820 cancer-related deaths in the United States. Therefore, the increasing prevalence of cancer is driving the demand for minimal residual disease testing.

Major companies in the minimal residual disease testing market are launching advanced cancer research testing solutions to enhance detection sensitivity, improve treatment monitoring, and promote precision medicine for better patient outcomes. For example, the IDT Archer FUSIONPlex Core Solid Tumor Panel is a next-generation sequencing assay used to detect gene fusions and mutations in solid tumors, supporting precision oncology and treatment decision-making. In April 2023, Integrated DNA Technologies (IDT), a U.S.-based provider of genomic solutions, launched this enhanced cancer research testing solution, now offering expanded and optimized coverage for single nucleotide variants (SNVs) and indels. This RNA-based sequencing assay simplifies fusion detection and variant calling in solid tumors, using a single sample input and providing researchers with a scalable, user-friendly solution that saves time, resources, and costs.

In April 2023, Quest Diagnostics, a U.S.-based clinical laboratory, acquired Haystack Oncology. Through this acquisition, Quest aims to enhance personalized cancer care by integrating Haystack's liquid biopsy technology, which detects residual or recurring cancer by identifying circulating tumor DNA (ctDNA) in the bloodstream. Haystack Oncology Inc. is a U.S.-based biotechnology company specializing in innovative cancer diagnostics.

Major companies operating in the minimal residual disease testing market are Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Luminex Corporation, Menarini Silicon Biosystems S.p.A.

North America was the largest region in the minimal residual disease testing market in 2025. The regions covered in the minimal residual disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the minimal residual disease testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The minimal residual disease testing market includes revenues earned by entities by providing services such as peripheral blood cell testing, sequencing testing, high-throughput sequencing testing, and methylation sequencing testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Minimal Residual Disease Testing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses minimal residual disease testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for minimal residual disease testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The minimal residual disease testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Test Type: DNA - Based Test; RNA- Based Test; Immunological Test
• 2) By Technology: Flow Cytometry; Polymerase Chain Reaction (PCR); Next-Generation Sequencing (NGS); Other Technologies
• 3) By Application: Hematological Malignancies; Leukemia; Lymphoma; Solid Tumors; Other Application
• 4) By End User: Hospitals And Specialty Clinics; Diagnostic Laboratories; Academic And Research Institutes; Other End Users
• Subsegments:
• 1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests; Next-Generation Sequencing (NGS); Digital PCR
• 2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR); RNA Sequencing; Quantitative PCR (qPCR)
• 3) By Immunological Test: Flow Cytometry; Enzyme-Linked Immunosorbent Assay (ELISA); Immunohistochemistry
• Companies Mentioned: Natera Inc.; Guardant Health Inc.; Laboratory Corporation of America Holdings; QIAGEN NV; F. Hoffmann-La Roche Ltd.; Bio-Techne Corporation; Bio-Rad Laboratories Inc.; Sysmex Corporation; Exact Sciences Corporation; GRAIL LLC; Veracyte Inc.; Cergentis B.V; Mdxhealth SA; NeoGenomics Laboratories Inc.; Adaptive Biotechnologies; Thermo Fisher Scientific Inc.; Siemens Healthineers AG; PerkinElmer Inc.; Agilent Technologies Inc.; ArcherDx Inc.; Asuragen Inc.; Becton Dickinson and Company; Cepheid Inc.; Fluidigm Corporation; Illumina Inc.; Invitae Corporation; Luminex Corporation; Menarini Silicon Biosystems S.p.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Minimal Residual Disease Testing Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Minimal Residual Disease Testing Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Minimal Residual Disease Testing Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Minimal Residual Disease Testing Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Liquid Biopsy Adoption
  • 4.2.2 Personalized Cancer Monitoring
  • 4.2.3 Early Detection & Prognosis Improvement
  • 4.2.4 Integration Of Molecular Diagnostics
  • 4.2.5 Expansion Of Oncology Research

5. Minimal Residual Disease Testing Market Analysis Of End Use Industries

• 5.1 Hospitals And Specialty Clinics
• 5.2 Diagnostic Laboratories
• 5.3 Academic And Research Institutes
• 5.4 Oncology Centers
• 5.5 Biotechnology Companies

6. Minimal Residual Disease Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Minimal Residual Disease Testing Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Minimal Residual Disease Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Minimal Residual Disease Testing Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Minimal Residual Disease Testing Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Minimal Residual Disease Testing Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Minimal Residual Disease Testing Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Minimal Residual Disease Testing Market Segmentation

• 9.1. Global Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• DNA - Based Test, RNA- Based Test, Immunological Test
• 9.2. Global Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
• 9.3. Global Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
• 9.4. Global Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users
• 9.5. Global Minimal Residual Disease Testing Market, Sub-Segmentation Of DNA-Based Test, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR
• 9.6. Global Minimal Residual Disease Testing Market, Sub-Segmentation Of RNA-Based Test, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)
• 9.7. Global Minimal Residual Disease Testing Market, Sub-Segmentation Of Immunological Test, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry

10. Minimal Residual Disease Testing Market Regional And Country Analysis

• 10.1. Global Minimal Residual Disease Testing Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Minimal Residual Disease Testing Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Minimal Residual Disease Testing Market

• 11.1. Asia-Pacific Minimal Residual Disease Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Minimal Residual Disease Testing Market

• 12.1. China Minimal Residual Disease Testing Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Minimal Residual Disease Testing Market

• 13.1. India Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Minimal Residual Disease Testing Market

• 14.1. Japan Minimal Residual Disease Testing Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Minimal Residual Disease Testing Market

• 15.1. Australia Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Minimal Residual Disease Testing Market

• 16.1. Indonesia Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Minimal Residual Disease Testing Market

• 17.1. South Korea Minimal Residual Disease Testing Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Minimal Residual Disease Testing Market

• 18.1. Taiwan Minimal Residual Disease Testing Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Minimal Residual Disease Testing Market

• 19.1. South East Asia Minimal Residual Disease Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Minimal Residual Disease Testing Market

• 20.1. Western Europe Minimal Residual Disease Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Minimal Residual Disease Testing Market

• 21.1. UK Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Minimal Residual Disease Testing Market

• 22.1. Germany Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Minimal Residual Disease Testing Market

• 23.1. France Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Minimal Residual Disease Testing Market

• 24.1. Italy Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Minimal Residual Disease Testing Market

• 25.1. Spain Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Minimal Residual Disease Testing Market

• 26.1. Eastern Europe Minimal Residual Disease Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Minimal Residual Disease Testing Market

• 27.1. Russia Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Minimal Residual Disease Testing Market

• 28.1. North America Minimal Residual Disease Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Minimal Residual Disease Testing Market

• 29.1. USA Minimal Residual Disease Testing Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Minimal Residual Disease Testing Market

• 30.1. Canada Minimal Residual Disease Testing Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Minimal Residual Disease Testing Market

• 31.1. South America Minimal Residual Disease Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Minimal Residual Disease Testing Market

• 32.1. Brazil Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Minimal Residual Disease Testing Market

• 33.1. Middle East Minimal Residual Disease Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Minimal Residual Disease Testing Market

• 34.1. Africa Minimal Residual Disease Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Minimal Residual Disease Testing Market, Segmentation By Test Type, Segmentation By Technology, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Minimal Residual Disease Testing Market Regulatory and Investment Landscape

36. Minimal Residual Disease Testing Market Competitive Landscape And Company Profiles

• 36.1. Minimal Residual Disease Testing Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Minimal Residual Disease Testing Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Minimal Residual Disease Testing Market Company Profiles
  • 36.3.1. Natera Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Guardant Health Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. QIAGEN NV Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Minimal Residual Disease Testing Market Other Major And Innovative Companies

• Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc.

38. Global Minimal Residual Disease Testing Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Minimal Residual Disease Testing Market

40. Minimal Residual Disease Testing Market High Potential Countries, Segments and Strategies

• 40.1 Minimal Residual Disease Testing Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Minimal Residual Disease Testing Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Minimal Residual Disease Testing Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer